Travelan Math Tells the Tale of Large 9-Figure Opportunity

Based on September 2018 sales of Travelan in Australia ($142,000 Australian dollars, or $102,240 U.S. dollars), a quick 12-month calculation shows that, based on those sales figures, Travelan should be selling $1,226,880 U.S. dollars in yearly sales in Australia.  Multiplying by a factor of 13.66 (U.S. population is 13.66x the size of Australian population), you get $16,759,180 U.S. dollars in annual sales in the United States.  Combined - that is $17.98 million in annual Travelan sales in the U.S. and Australia combined. And this is simply assuming Travelan finds the same level of adoption in the United States that it has in Australia..  It's possible the uptake could be far greater in the United States (in fact, it's extremely likely) with big pharma money behind the scenes to promote it. 

Running the same math for Western Europe only, which is 8.1x larger than the Australian population (200M people compared to 24M people), that adds another $10M in sales coming from the Western Europe countries.  That gets Travelan up to $28 million in yearly sales among the United States, Australia, and Western Europe folks.  Japan would also add another $6.44 million in yearly sales, so we are now up to $35 million in yearly sales of Travelan if Travelan can reach the same level of current market adoption it has in Australia.  And again, with real money (big pharma) behind the product, you'd expect the uptake to be much, much greater.

When you factor in the rest of the world (China, India, Russia, the rest of Asia, Brazil, etc.), the market for Travelan solely for the international traveler is over $100 million dollars.  And then, when you factor in what Travelan as an oral vaccine candidate for ETEC/Shigella is worth to a GSK or Merck in Africa and other parts of the developing world where children are in dying from Shigella/ETEC/Campy infections, you can easily add another $100 million in value to Travelan.

A very realistic $200 million dollar market opportunity before we even talk about IMM-124E or IMM-529E for NASH, ASH, P.NAFLD, colitis, or C.Dif.